Effect of AD-5423 on animal models of schizophrenia: Phencyclidine-induced behavioral changes in mice

T. Nagai, Y. Noda, T. Une, K. Furukawa, H. Furukawa, Q. M. Kan, T. Nabeshima

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT2 and a dopamine D2 receptor antagonist, was evaluated using animal models of schizophrenia. Sensitization to phencyclidine (PCP)-induced hyperlocomotion is considered a model of the positive symptoms of schizophrenia, and was significantly antagonized by AD-5423 and haloperidol. The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia, was attenuated by AD-5423 but not by haloperidol. Since this attenuated effect of AD-5423 was antagonized by DOI, a serotonin 5-HT2 receptor agonist, it is postulated to be mediated by serotonin 5-HT2 receptors. These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia.

Original languageEnglish
Pages (from-to)269-272
Number of pages4
JournalNeuroreport
Volume14
Issue number2
DOIs
Publication statusPublished - 10-02-2003

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Effect of AD-5423 on animal models of schizophrenia: Phencyclidine-induced behavioral changes in mice'. Together they form a unique fingerprint.

  • Cite this